Status:
COMPLETED
Duloxetine for Chronic Depression: a Double-blind Study
Lead Sponsor:
New York State Psychiatric Institute
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Dysthymic Disorder
Depressive Disorder NOS
Eligibility:
All Genders
20-75 years
Phase:
PHASE4
Brief Summary
The investigators are studying a new antidepressant medicine, duloxetine, for the treatment of people with chronic depression. Duloxetine (trade name Cymbalta) was recently approved by the FDA for the...
Detailed Description
This is a 22-week study of the tolerability, dosing, and efficacy of duloxetine in chronically depressed outpatients. Participants can have Dysthymic Disorder (Dysthymia), or Depression, Not Otherwise...
Eligibility Criteria
Inclusion
- age 20 to 75 years (ages 20 to 60 for MRI sub-study)
- diagnosis of dysthymic disorder (chronic depression) or depression NOS
- minimum of 2 years duration of current episode of depression
Exclusion
- current major depression
- diagnoses including delirium, dementia, bipolar disorder, schizophrenia
- substance abuse or dependence in the past 6 months
- pregnant or nursing women
- serious risk of suicide
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT00360724
Start Date
August 1 2006
End Date
December 1 2013
Last Update
August 21 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
New York State Psychiatric Institute
New York, New York, United States, 10032